Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis

- Glucocorticosteroid (GCS) continuous to decrease in Germany.
- Natalizumab utilization decreased with the emergence of additional treatment options.
- GCS utilization decreases for both RRMS and SPMS.
- The generally observed decrease in relapses per year is confirmed with in the data.